RELMADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
RELMADA THERAPEUTICS, INC. (RLMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 13.05 million shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-19.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2024-03-19
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2022-09-29 was 260.00K shares.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2022-03-31 was 10.00K shares, a 99.33% decline year-over-year.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2021-03-31 was 1.50M shares.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 13.05M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 2 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | 13.05M shares 10-K · filed 2024-03-19 | ||||
| 2023-09-18 | 10.00K shares 10-K · filed 2024-03-19 | ||||
| 2023-06-20 | 60.00K shares 10-K · filed 2024-03-19 | ||||
| 2023-02-21 | 620.00K shares 10-K · filed 2024-03-19 | ||||
| 2022-09-29 | 260.00K shares 10-K · filed 2024-03-19 | ||||
| 2022-05-05 | 260.00K shares 10-K · filed 2024-03-19 | ||||
| 2022-03-31 | 10.00K shares 10-Q · filed 2022-05-05 | ||||
| 2022-03-28 | 15.00K shares 10-K · filed 2024-03-19 | ||||
| 2022-03-14 | 110.00K shares 10-K · filed 2024-03-19 | ||||
| 2021-12-22 | 5.01M shares 10-K · filed 2024-03-19 | ||||
| 2021-03-31 | 1.50M shares 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |